Primary care providers' perspectives on discontinuing prostate cancer screening

Cancer

Volumn 118, Issue 22, 2012, Pages 5518-5524

  Pollack, Craig E ^a,b   Platz, Elizabeth A ^b   Bhavsar, Nrupen A ^a,b   Noronha, Gary ^c   Green, Gene E ^c   Chen, Sean ^a   Carter, H Ballentine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

cancer screening; life expectancy; primary care provider; prostate cancer screening; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; BIVARIATE ANALYSIS; CANCER SCREENING; ETHNIC GROUP; FEMALE; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; MALE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

AGE FACTORS; DECISION MAKING; EARLY DETECTION OF CANCER; FEMALE; HEALTH PLANNING GUIDELINES; HUMANS; LIFE EXPECTANCY; MALE; MASS SCREENING; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 84868195314     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27577     Document Type: Review

References (30)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
2. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program 407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009; 30: 81-87.
3. Macefield RC, Metcalfe C, Lane JA, et al. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer. 2010; 102: 1335-1340.
4. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM,. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011; 186: 1830-1834.
5. Balderson N, Towell T,. The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support. Br J Health Pscyhol. 2003; 8: 125-134.
6. Cliff AM, MacDonagh RP,. Psychosocial morbidity in prostate cancer: II. A comparison of patients and partners. BJU Int. 2000; 86: 834-839.
7. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
8. Snyder CF, Frick KD, Blackford AL, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010; 116: 5391-5399.
9. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ,. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer. 2009; 101: 1833-1838.
10. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008; 100: 630-641.
11. Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML,. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
12. Chou R, LeFevre ML,. Prostate cancer screening-the evidence, the recommendations, and the clinical implications. JAMA. 2011; 306: 2721-2722.
13. Bellizzi KM, Breslau ES, Burness A, Waldron W,. Prevalence of cancer screening in older, racially diverse adults: still screening after all these years. Arch Intern Med. 2011; 171: 2031-2037.
14. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE,. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011; 29: 1736-1743.
15. Hoffman RM, Couper MP, Zikmund-Fisher BJ, et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med. 2009; 169: 1611-1618.
16. Lewis CL, Griffith J, Pignone MP, Golin C,. Physicians' decisions about continuing or stopping colon cancer screening in the elderly: a qualitative study. J Gen Intern Med. 2009; 24: 816-821.
17. Lewis CL, Moore CG, Golin CE, Griffith J, Tytell-Brenner A, Pignone MP,. Resident physicians' life expectancy estimates and colon cancer screening recommendations in elderly patients. Med Decis Making. 2008; 28: 254-261.
18. Dunn AS, Shridharani KV, Lou W, Bernstein J, Horowitz CR,. Physician-patient discussions of controversial cancer screening tests. Am J Prev Med. 2001; 20: 130-134.
19. Guerra CE, Jacobs SE, Holmes JH, Shea JA,. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. J Gen Intern Med. 2007; 22: 901-907.
20. Linder SK, Hawley ST, Cooper CP, Scholl LE, Jibaja-Weiss M, Volk RJ,. Primary care physicians reported use of pre-screening discussions for prostate cancer screening: a cross-sectional survey [serial online]. BMC Fam Pract. 2009; 10: 19.
21. Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK,. Prognostic indices for older adults. JAMA. 2012; 307: 182-192.
22. Lewis CL, Kistler CE, Amick HR, et al. Older adults' attitudes about continuing cancer screening later in life: a pilot study interviewing residents of 2 continuing care communities [serial online]. BMC Geriatrics. 2006; 6: 10.
23. Back AL, Arnold RM,. Discussing prognosis: "how much do you want to know?" Talking to patients who do not want information or who are ambivalent. J Clin Oncol. 2006; 24: 4314-4217.
24. Smith AK, Williams BA, Lo B,. Discussing overall prognosis with the very elderly. N Engl J Med. 2011; 365: 2149-2151.
25. Davis K, Haisfield L, Dorfman C, Krist A, Taylor KL,. Physicians' attitudes about shared decision making for prostate cancer screening. Fam Med. 2011; 43: 260-266.
26. Agency for Health Care Research and Quality (AHRQ). Patient Centered Medical Home Resource Center: Defining the PCMH. Rockville, MD: AHRQ; 2012. Available at: http://pcmh.ahrq.gov/portal/server.pt/community/pcmh-home/1483/ PCMH-Defining% 20the%20PCMH-version 2. Accessed February 6, 2012.
27. Hall I, Taylor Y, Ross L, Richardson L, Richards T, Rim S,. Discussions about prostate cancer screening between US primary care physicians and their patients. J Gen Intern Med. 2011; 26: 1098-1104.
28. Stroud L, Ross LE, Rose SW,. Formative evaluation of the prostate cancer screening practices of African-American physicians. J Natl Med Assoc. 2006; 98: 1637-1643.
29. Schaeffer EM, Carter HB, Ketterman A, et al. Prostate specific antigen testing among the elderly-when to stop? J Urol. 2009; 181: 1606-1614.
30. Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Moul JW, Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU Int. 2010; 108: 44-48.